RecruitingPhase 2NCT07146906

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

An Open-label, Multicenter Study to Assess the Effect of Zigakibart Treatment on Histologic, Circulating, and Excreted Markers of Kidney Disease and Dysfunction in Adult Patients With IgA Nephropathy.

Sponsor

Novartis Pharmaceuticals

Enrollment

32 participants

Start Date

Mar 26, 2026

Study Type

INTERVENTIONAL

Conditions

Immunoglobulin A Nephropathy (IgAN)

Summary

The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called zigakibart for people with immunoglobulin a nephropathy (igan). The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years to 100 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALzigakibart

zigakibart 600 mg sc injections every second week for 104 weeks (2 years)

Locations(26)

Colorado Kidney Care Nephrology

Denver, Colorado, United States

American Clinical Trials

Acworth, Georgia, United States

Univ Of Iowa Hospitals And Clinics

Iowa City, Iowa, United States

Inter Med Consultants

Edina, Minnesota, United States

Novartis Investigative Site

Serra, Espírito Santo, Brazil

Novartis Investigative Site

Botucatu, São Paulo, Brazil

Novartis Investigative Site

Beijing, China

Novartis Investigative Site

Shanghai, China

Novartis Investigative Site

Munich, Bavaria, Germany

Novartis Investigative Site

Hanover, Germany

Novartis Investigative Site

Mainz, Germany

Novartis Investigative Site

Ranica, BG, Italy

Novartis Investigative Site

Brescia, BS, Italy

Novartis Investigative Site

Pavia, PV, Italy

Novartis Investigative Site

Kawasaki, Kanagawa, Japan

Novartis Investigative Site

Miyazaki, Japan

Novartis Investigative Site

Lodz, Poland

Novartis Investigative Site

Opole, Poland

Novartis Investigative Site

Seoul, Seoul, South Korea

Novartis Investigative Site

Seoul, South Korea

Novartis Investigative Site

Pamplona, Navarre, Spain

Novartis Investigative Site

Valencia, Valencia, Spain

Novartis Investigative Site

Barcelona, Spain

Novartis Investigative Site

Seville, Spain

Novartis Investigative Site

Kaohsiung City, Taiwan

Novartis Investigative Site

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07146906

Related Trials

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06935357251 locations

Chinese Adults With Kidney Disease

NCT0752209910 locations